These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 27863358)

  • 1. Temporal trends and long term follow-up of implantable cardioverter defibrillator therapy for secondary prevention: A 15-year single-centre experience.
    Caputo ML; Regoli F; Conte G; Adjibodou B; Svab S; Del Bufalo A; Moccetti T; Curti M; Klersy C; Auricchio A
    Int J Cardiol; 2017 Feb; 228():31-36. PubMed ID: 27863358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcome of implantable cardioverter-defibrillator implantation in secondary prevention of sudden cardiac death.
    Boulé S; Sémichon M; Guédon-Moreau L; Drumez É; Kouakam C; Marquié C; Brigadeau F; Kacet S; Potelle C; Escande W; Souissi Z; Lacroix D; Duhamel A; Klug D
    Arch Cardiovasc Dis; 2016 Oct; 109(10):517-526. PubMed ID: 27342808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of and predictors for appropriate implantable cardioverter-defibrillator therapy in patients with a secondary preventive implantable cardioverter-defibrillator indication.
    Schaer B; Kühne M; Reichlin T; Osswald S; Sticherling C
    Europace; 2016 Feb; 18(2):227-31. PubMed ID: 26063686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Chronic Total Coronary Occlusion on Recurrence of Ventricular Arrhythmias in Ischemic Secondary Prevention Implantable Cardioverter-Defibrillator Recipients (VACTO Secondary Study): Insights From Coronary Angiogram and Electrogram Analysis.
    Nombela-Franco L; Iannaccone M; Anguera I; Amat-Santos IJ; Sanchez-Garcia M; Bautista D; Calvelo MN; Di Marco A; Moretti C; Pozzi R; Scaglione M; Cañadas V; Sandin-Fuentes M; Arenal A; Bagur R; Perez-Castellano N; Fernandez-Perez C; Gaita F; Macaya C; Escaned J; Fernández-Lozano I
    JACC Cardiovasc Interv; 2017 May; 10(9):879-888. PubMed ID: 28473110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up of patients with cardiac sarcoidosis and implantable cardioverter-defibrillators.
    Betensky BP; Tschabrunn CM; Zado ES; Goldberg LR; Marchlinski FE; Garcia FC; Cooper JM
    Heart Rhythm; 2012 Jun; 9(6):884-91. PubMed ID: 22338670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of long detection interval implantable cardioverter-defibrillator settings in secondary prevention population: data from the Avoid Delivering Therapies for Nonsustained Arrhythmias in ICD Patients III (ADVANCE III) trial.
    Kloppe A; Proclemer A; Arenal A; Lunati M; Martìnez Ferrer JB; Hersi A; Gulaj M; Wijffels MC; Santi E; Manotta L; Mangoni L; Gasparini M
    Circulation; 2014 Jul; 130(4):308-14. PubMed ID: 24838360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Appropriate implantable cardioverter-defibrillator interventions in cardiac resynchronization therapy-defibrillator (CRT-D) patients undergoing device replacement: time to downgrade from CRT-D to CRT-pacemaker? Insights from real-world clinical practice in the DECODE CRT-D analysis.
    Narducci ML; Biffi M; Ammendola E; Vado A; Campana A; Potenza DR; Iori M; Zanon F; Zacà V; Zoni Berisso M; Bertini M; Lissoni F; Bandini A; Malacrida M; Crea F
    Europace; 2018 Sep; 20(9):1475-1483. PubMed ID: 29186401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival and appropriate device interventions in recipients of cardioverter defibrillators implanted for the primary versus secondary prevention of sudden cardiac death.
    Stockburger M; Krebs A; Nitardy A; Habedank D; Celebi O; Knaus T; Dietz R
    Pacing Clin Electrophysiol; 2009 Mar; 32 Suppl 1():S16-20. PubMed ID: 19250084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Avoiding Untimely Implantable Cardioverter/Defibrillator Implantation by Intensified Heart Failure Therapy Optimization Supported by the Wearable Cardioverter/Defibrillator-The PROLONG Study.
    Duncker D; König T; Hohmann S; Bauersachs J; Veltmann C
    J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28096098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes in patients with sustained ventricular tachyarrhythmias occurring within 48 h of acute myocardial infarction: when is ICD appropriate?
    Liang JJ; Hodge DO; Mehta RA; Russo AM; Prasad A; Cha YM
    Europace; 2014 Dec; 16(12):1759-66. PubMed ID: 25100756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Arrhythmia, device interventions and mortality analysis in patients with implanted cardioverter-defibrillator with/without resynchronisation therapy in dilative cardiomyopathy in primary prevention of sudden cardiac death].
    Lelakowski J; Pudło J; Lelakowska-Pieła M; Rydlewska A; Piekarz J; Domaracki D
    Pol Merkur Lekarski; 2016 Apr; 40(238):216-22. PubMed ID: 27137820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrence of ventricular arrhythmias in ischaemic secondary prevention implantable cardioverter defibrillator recipients: long-term follow-up of the Leiden out-of-hospital cardiac arrest study (LOHCAT).
    Borleffs CJ; van Erven L; Schotman M; Boersma E; Kiès P; van der Burg AE; Zeppenfeld K; Bootsma M; van der Wall EE; Bax JJ; Schalij MJ
    Eur Heart J; 2009 Jul; 30(13):1621-6. PubMed ID: 19493865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of the subcutaneous implantable cardioverter-defibrillator in patients with a primary prevention indication with and without a reduced ejection fraction versus patients with a secondary prevention indication.
    Boersma LV; Barr CS; Burke MC; Leon AR; Theuns DA; Herre JM; Weiss R; Kremers MS; Neuzil P; Husby MP; Carter N; Stivland TM; Gold MR;
    Heart Rhythm; 2017 Mar; 14(3):367-375. PubMed ID: 27890798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term incidence of malignant ventricular arrhythmia and shock therapy in patients with primary defibrillator implantation does not differ from event rates in patients treated for survived cardiac arrest.
    Backenköhler U; Erdogan A; Steen-Mueller MK; Kuhlmann C; Most A; Schaefer C; Stertmann W; Waas W; Tillmanns H; Waldecker B
    J Cardiovasc Electrophysiol; 2005 May; 16(5):478-82. PubMed ID: 15877617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers Of Ventricular Arrhythmias (TOVA) study.
    Whang W; Mittleman MA; Rich DQ; Wang PJ; Ruskin JN; Tofler GH; Muller JE; Albert CM;
    Circulation; 2004 Mar; 109(11):1386-91. PubMed ID: 14993132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rates and predictors of appropriate implantable cardioverter-defibrillator therapy delivery: results from the EVADEF cohort study.
    Otmani A; Trinquart L; Marijon E; Lavergne T; Waintraub X; Lepillier A; Chatellier G; Le Heuzey JY;
    Am Heart J; 2009 Aug; 158(2):230-237.e1. PubMed ID: 19619699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
    JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.